Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 1/2 1Phase 1 1

Status

Completed 7Active not recruiting 6Withdrawn 3Terminated 3Recruiting 3Unknown 2Not yet recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 6Gastrointestinal 4Genitourinary 3Breast 3Sarcoma 2Other solid neoplasm 1Lymphoid 1CNS 1

Conditions

Breast Neoplasms 3Sarcoma 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1

Interventions

Paclitaxel 31Cyclophosphamide 25Trastuzumab 23Doxorubicin 17Docetaxel 15Carboplatin 15pembrolizumab 13Radiotherapy 11Letrozole 11Capecitabine 11exemestane 10Fulvestrant 10Magnetic Resonance Spectroscopy 8Lapatinib 8Biopsy 8eribulin 7abemaciclib 7Taxes 7Bevacizumab 7Anastrozole 7pertuzumab 6palbociclib 6Neoadjuvant Therapy 6Goserelin 6Drug Therapy 6Aromatase Inhibitors 6130-nm albumin-bound paclitaxel 6Therapeutics 5Saline Solution 5Radiosurgery 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Withdrawn × niraparib × Breast × Clear all
NCT05238831 2024-01-23

SMMART Adaptive Clinical Treatment (ACT) Trial

OHSU Knight Cancer Institute

Phase EARLY_PHASE1 Withdrawn
BreastGastrointestinalGenitourinaryGynecologicSarcoma

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma

NCT04762901 2022-04-26

LCI-BRE-MTN-NIR-001:Ph I Study of Niraparib in Combo With Standard Chemo in Metastatic Trip Neg Breast Cancer

Wake Forest University Health Sciences

Phase 1 Withdrawn
Breast

Breast Neoplasms

NCT04655183 2021-06-30

Study of M4344 in Combination With Niraparib

EMD Serono

Phase 1/2 Withdrawn
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡